Current concepts in PD-L1 testing in head and neck squamous cell carcinoma: overview, developments and challenges

Cancer immunotherapy is arguably the biggest success story of personalized medicine in the past two decades. Monoclonal antibodies targeting immune checkpoint inhibitors like PD-1 have shown success in clinical trials in a variety of solid tumours. The histopathologist has a central role in determining patient eligibility for immunotherapy by virtue of the histological assessment of tumours and their characterization of the tumour immune microenvironment. There is now a plethora of companion diagnostic PD-L1 immunohistochemical assays for use across multiple tumour types and platforms.
Source: Diagnostic Histopathology - Category: Pathology Authors: Tags: Mini-symposium: head and neck pathology Source Type: research